Literature DB >> 20110173

Stereoselective synthesis of desloratadine derivatives as antagonist of histamine.

Gai-Zhi Liu1, Hai-Wei Xu, Guang-Wei Chen, Peng Wang, Ya-Na Wang, Hong-Min Liu, De-Quan Yu.   

Abstract

A series of desloratadine derivatives were stereoselectively synthesized and evaluated for H(1) antihistamine activity. For the evaluation of H(1) antihistamine activity, the in vitro histamine-induced contraction of the guinea-pig ileum assay (HC) was used. The synthesized desloratadine derivatives 7, 8 and 9 are structurally related to rupatadine and were generated by replacement of the 5-methyl-3-pyridine group of rupatadine with gamma-alkylidene butenolide. Their H(1) antihistamine activities have shown a high dependence on the exact nature of the substituent in the lactone ring. Optimum structures 7, 8a and 8g display potent activity inhibiting histamine-induced effects. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110173     DOI: 10.1016/j.bmc.2009.12.061

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1.

Authors:  Paul C Trippier; Radhia Benmohamed; Radhia Benmohammed; Donald R Kirsch; Richard B Silverman
Journal:  Bioorg Med Chem Lett       Date:  2012-09-07       Impact factor: 2.823

2.  Cyclizations of phenylethyl-substituted pyridinecarboxaldehydes.

Authors:  Rajasekhar Reddy Naredla; Douglas A Klumpp
Journal:  Tetrahedron       Date:  2013-03-04       Impact factor: 2.457

3.  High pressure assisted synthetic approach for novel 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-b]pyridine and 5,6-dihydrobenzo[h]quinoline derivatives and their assessment as anticancer agents.

Authors:  Haider Behbehani; Fatemah A Aryan; Kamal M Dawood; Hamada Mohamed Ibrahim
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.